Cellaria Cell Models & Media
BioreclamationIVT, Authorized Distributor For:
BioreclamationIVT expands its offering of cellular products directed at oncology research through its partnership with Cellaria to offer their novel cancer cell lines and cancer culture media.
Designed to accelerate cancer research, the Cellaria cell models are derived directly from patient tumors with fully consented, fully documented pathological data. A unique feature of the cell models is their ability to maintain the fidelity of primary cells, with no genetic manipulation, while still offering the long-term reproducibility and scalability seen with traditional tumor cell lines. In addition to the cell lines, BioreclamationIVT will also distribute Cellaria's proprietary media which is specifically formulated to extend in vitro propagation of primary tumor and epithelial cells.
Where established testing methods fall short, Cellaria fills the gap.
Providing sustained growth through innovation and optimization
Today’s researchers find it challenging to find representative tumor-derived cell lines and so the scope of research around personalized medicine is restricted. In fact, some rare cancer sub-types have no models at all.
Cellaria’s technology enables greater success in generating cell models from patient tumors, for both easy and difficult to grow cancers. By supporting consistent growth of multiple cell types within the tumor, the Cellaria media and proprietary protocols prevent cell death and cell selection which is often seen with traditional cell culture methods.
Exceptional Quality and Reproducibility
Reproducibility is key in producing high quality data with relevant results.
For each lot of cells, the following tests are performed:
- Microbial and human viral contamination
- STR fingerprinting to confirm authenticate the cells
- Expected growth performance, up to three passages after thaw
Cell characteristics that reflect true clinical attributes
Using the primary tumor as a reference, Cellaria scientists have accurately preserved the cancer cells within the tumor sample. Each model is supplied with extensive clinical information and highlights of critical mutations and/or molecular markers to confirm the identity of each cell model. With these novel cell models, researchers can bridge the gap between in vitro models and oncology patient populations.